Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.

Uganda's experience in Ebola virus disease outbreak preparedness, 2018-2019.

Aceng JR, Ario AR, Muruta AN, Makumbi I, Nanyunja M, Komakech I, Bakainaga AN, Talisuna AO, Mwesigye C, Mpairwe AM, Tusiime JB, Lali WZ, Katushabe E, Ocom F, Kaggwa M, Bongomin B, Kasule H, Mwoga JN, Sensasi B, Mwebembezi E, Katureebe C, Sentumbwe O, Nalwadda R, Mbaka P, Fatunmbi BS, Nakiire L, Lamorde M, Walwema R, Kambugu A, Nanyondo J, Okware S, Ahabwe PB, Nabukenya I, Kayiwa J, Wetaka MM, Kyazze S, Kwesiga B, Kadobera D, Bulage L, Nanziri C, Monje F, Aliddeki DM, Ntono V, Gonahasa D, Nabatanzi S, Nsereko G, Nakinsige A, Mabumba E, Lubwama B, Sekamatte M, Kibuule M, Muwanguzi D, Amone J, Upenytho GD, Driwale A, Seru M, Sebisubi F, Akello H, Kabanda R, Mutengeki DK, Bakyaita T, Serwanjja VN, Okwi R, Okiria J, Ainebyoona E, Opar BT, Mimbe D, Kyabaggu D, Ayebazibwe C, Sentumbwe J, Mwanja M, Ndumu DB, Bwogi J, Balinandi S, Nyakarahuka L, Tumusiime A, Kyondo J, Mulei S, Lutwama J, Kaleebu P, Kagirita A, Nabadda S, Oumo P, Lukwago R, Kasozi J, Masylukov O, Kyobe HB, Berdaga V, Lwanga M, Opio JC, Matseketse D, Eyul J, Oteba MO, Bukirwa H, Bulya N, Masiira B, Kihembo C, Ohuabunwo C, Antara SN, Owembabazi W, Okot PB, Okwera J, Amoros I, Kajja V, Mukunda BS, Sorela I, Adams G, Shoemaker T, Klena JD, Taboy CH, Ward SE, Merrill RD, Carter RJ, Harris JR, Banage F, Nsibambi T, Ojwang J, Kasule JN, Stowell DF, Brown VR, Zhu BP, Homsy J, Nelson LJ, Tusiime PK, Olaro C, Mwebesa HG, Woldemariam YT.

Global Health. 2020 Mar 19;16(1):24. doi: 10.1186/s12992-020-00548-5.

3.

A Pilot Test of Game Changers, a Social Network Intervention to Empower People with HIV to be Prevention Advocates in Uganda.

Bogart LM, Matovu JKB, Wagner GJ, Green HD, Storholm ED, Klein DJ, Marsh T, MacCarthy S, Kambugu A.

AIDS Behav. 2020 Feb 6. doi: 10.1007/s10461-020-02806-4. [Epub ahead of print]

PMID:
32030525
4.

Peer distribution of HIV self-test kits to men who have sex with men to identify undiagnosed HIV infection in Uganda: A pilot study.

Okoboi S, Lazarus O, Castelnuovo B, Nanfuka M, Kambugu A, Mujugira A, King R.

PLoS One. 2020 Jan 23;15(1):e0227741. doi: 10.1371/journal.pone.0227741. eCollection 2020.

5.

Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control study.

Buzibye A, Musaazi J, von Braun A, Nanzigu S, Sekaggya-Wiltshire C, Kambugu A, Fehr J, Lamorde M, Gutteck U, Muller D, Sowinski S, Reynolds SJ, Castelnuovo B.

AIDS Res Ther. 2019 Dec 6;16(1):39. doi: 10.1186/s12981-019-0255-x.

6.

Bending the Arc towards Equitable Partnerships in Global Health and Applied Training.

Martin NA, Kalbarczyk A, Nagourney E, Reich A, Hansoti B, Kambugu A, Quinn TC, Manabe YC, Castelnuovo B.

Ann Glob Health. 2019 Nov 6;85(1):130. doi: 10.5334/aogh.2564.

7.

Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations.

Bongomin F, Govender NP, Chakrabarti A, Robert-Gangneux F, Boulware DR, Zafar A, Oladele RO, Richardson MD, Gangneux JP, Alastruey-Izquierdo A, Bazira J, Boyles TH, Sarcarlal J, Nacher M, Obayashi T, Worodria W, Pasqualotto AC, Meya DB, Cheng B, Sriruttan C, Muzoora C, Kambugu A, Rodriguez Tudela JL, Jordan A, Chiller TM, Denning DW.

Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584. doi: 10.1007/s10096-019-03600-4. No abstract available.

PMID:
31175479
8.

Acceptability, perceived reliability and challenges associated with distributing HIV self-test kits to young MSM in Uganda: a qualitative study.

Okoboi S, Twimukye A, Lazarus O, Castelnuovo B, Agaba C, Immaculate M, Nanfuka M, Kambugu A, King R.

J Int AIDS Soc. 2019 Mar;22(3):e25269. doi: 10.1002/jia2.25269.

9.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

10.

A decade of antiretroviral therapy in Uganda: what are the emerging causes of death?

Kiragga AN, Mubiru F, Kambugu AD, Kamya MR, Castelnuovo B.

BMC Infect Dis. 2019 Jan 21;19(1):77. doi: 10.1186/s12879-019-3724-x.

11.

Incidence rate of sexually transmitted infections among HIV infected patients on long-term ART in an urban and a rural clinic in Uganda.

Okoboi S, Castelnuovo B, Moore DM, Musaazi J, Kambugu A, Birungi J, Nanfuka M, Van Rie A.

BMC Public Health. 2019 Jan 18;19(1):87. doi: 10.1186/s12889-019-6417-x.

12.

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.

Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Ripin DHB, Vos A, Kumarasamy N.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):224-233. doi: 10.1097/QAI.0000000000001908.

13.

Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options.

Baumann A, Musaazi J, Kambugu A, Kälin M, Weissberg D, Ssemwanga D, Fehr J, Castelnuovo B, Sekaggya-Wiltshire C, von Braun A.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):481-487. doi: 10.1097/QAI.0000000000001943.

PMID:
30633041
14.

Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.

Vos AG, Chersich MF, Klipstein-Grobusch K, Zuithoff P, Moorhouse MA, Lalla-Edward ST, Kambugu A, Kumarasamy N, Grobbee DE, Barth RE, Venter WD.

Retrovirology. 2018 Dec 14;15(1):77. doi: 10.1186/s12977-018-0460-z.

15.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
16.

Efficacy and safety of tenofovir disoproxil fumarate versus low-dose stavudine over 96 weeks: a multi-country randomised, non-inferiority trial.

Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, Arulappan N, Moorhouse M, Majam M, Akpomiemie G, Sokhela S, Poongulali S, Feldman C, Duncombe C, Brown Ripin DH, Kumarasamy N.

J Acquir Immune Defic Syndr. 2018 Nov 12. doi: 10.1097/QAI.0000000000001908. [Epub ahead of print]

PMID:
30422900
17.

Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.

Weissberg D, Mubiru F, Kambugu A, Fehr J, Kiragga A, von Braun A, Baumann A, Kaelin M, Sekaggya-Wiltshire C, Kamya M, Castelnuovo B.

PLoS One. 2018 Nov 1;13(11):e0206796. doi: 10.1371/journal.pone.0206796. eCollection 2018.

18.

Risky sexual behavior among patients on long-term antiretroviral therapy: a prospective cohort study in urban and rural Uganda.

Okoboi S, Castelnuovo B, Moore DM, Musaazi J, Kambugu A, Birungi J, Kaleebu P, Nanfuka M, Kamya MR, Van Rie A.

AIDS Res Ther. 2018 Oct 19;15(1):15. doi: 10.1186/s12981-018-0203-1.

19.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
20.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.

Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugyenyi P, Walker AS, Paton NI; Europe–Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Clin Infect Dis. 2019 Mar 19;68(7):1184-1192. doi: 10.1093/cid/ciy589.

21.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

22.

Correction of estimates of retention in care among a cohort of HIV-positive patients in Uganda in the period before starting ART: a sampling-based approach.

Nyakato P, Kiragga AN, Kambugu A, Bradley J, Baisley K.

BMJ Open. 2018 Apr 20;8(4):e017487. doi: 10.1136/bmjopen-2017-017487.

23.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

24.

Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.

Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS.

Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.

25.

Detection of tuberculosis patterns in digital photographs of chest X-ray images using Deep Learning: feasibility study.

Becker AS, Blüthgen C, Phi van VD, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Fehr J, Frauenfelder T.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):328-335. doi: 10.5588/ijtld.17.0520.

PMID:
29471912
26.

Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.

Castelnuovo B, Mubiru F, Kiragga AN, Musomba R, Mbabazi O, Gonza P, Kambugu A, Ratanshi RP.

BMJ Open. 2018 Feb 21;8(2):e015490. doi: 10.1136/bmjopen-2016-015490.

27.

Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid.

Kwizera R, Akampurira A, Kandole TK, Nabaggala MS, Williams DA, Kambugu A, Meya DB, Rhein J, Boulware DR; ASTRO Team.

Med Mycol. 2018 Jul 1;56(5):559-564. doi: 10.1093/mmy/myx076.

28.

Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa.

Holmes CB, Yiannoutsos CT, Elul B, Bukusi E, Ssali J, Kambugu A, Musick BS, Cohen C, Williams C, Diero L, Padian N, Wools-Kaloustian KK.

PLoS One. 2018 Jan 17;13(1):e0190828. doi: 10.1371/journal.pone.0190828. eCollection 2018.

29.

Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy.

Flynn AG, Anguzu G, Mubiru F, Kiragga AN, Kamya M, Meya DB, Boulware DR, Kambugu A, Castelnuovo BC.

PLoS One. 2017 Dec 15;12(12):e0189055. doi: 10.1371/journal.pone.0189055. eCollection 2017.

30.

Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis.

Kwizera R, Parkes-Ratanshi R, Page ID, Sekaggya-Wiltshire C, Musaazi J, Fehr J, Castelnuovo B, Kambugu A, Denning DW.

BMC Pulm Med. 2017 Nov 21;17(1):149. doi: 10.1186/s12890-017-0500-9.

31.

Key bottlenecks to the provision of safe obstetric anaesthesia in low- income countries; a cross-sectional survey of 64 hospitals in Uganda.

Epiu I, Wabule A, Kambugu A, Mayanja-Kizza H, Tindimwebwa JVB, Dubowitz G.

BMC Pregnancy Childbirth. 2017 Nov 17;17(1):387. doi: 10.1186/s12884-017-1566-3.

32.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.

33.

Text Messaging for Improving Antiretroviral Therapy Adherence: No Effects After 1 Year in a Randomized Controlled Trial Among Adolescents and Young Adults.

Linnemayr S, Huang H, Luoto J, Kambugu A, Thirumurthy H, Haberer JE, Wagner G, Mukasa B.

Am J Public Health. 2017 Dec;107(12):1944-1950. doi: 10.2105/AJPH.2017.304089. Epub 2017 Oct 19.

34.

Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.

Sekaggya-Wiltshire C, Castelnuovo B, von Braun A, Musaazi J, Muller D, Buzibye A, Gutteck U, Henning L, Ledergerber B, Corti N, Lamorde M, Fehr J, Kambugu A.

BMJ Open. 2017 Sep 18;7(9):e014679. doi: 10.1136/bmjopen-2016-014679.

35.

Evaluation of trypan blue stain in a haemocytometer for rapid detection of cerebrospinal fluid sterility in HIV patients with cryptococcal meningitis.

Kwizera R, Akampurira A, Kandole TK, Nielsen K, Kambugu A, Meya DB, Boulware DR, Rhein J; ASTRO-CM Study Team.

BMC Microbiol. 2017 Aug 22;17(1):182. doi: 10.1186/s12866-017-1093-4.

36.

Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial.

Wanyama JN, Nabaggala MS, Wandera B, Kiragga AN, Castelnuovo B, Mambule IK, Nakajubi J, Kambugu AD, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P.

Int J STD AIDS. 2018 Mar;29(3):287-297. doi: 10.1177/0956462417724707. Epub 2017 Aug 17.

PMID:
28814161
37.

Tuberculosis treatment success among rural and urban Ugandans living with HIV: a retrospective study.

Musaazi J, Kiragga AN, Castelnuovo B, Kambugu A, Bradley J, Rehman AM.

Public Health Action. 2017 Jun 21;7(2):100-109. doi: 10.5588/pha.16.0115.

38.

Hazardous alcohol consumption is not associated with CD4+ T-cell count decline among PLHIV in Kampala Uganda: A prospective cohort study.

Wandera B, Tumwesigye NM, Nankabirwa JI, Kambugu AD, Mafigiri DK, Kapiga S, Sethi AK.

PLoS One. 2017 Jun 30;12(6):e0180015. doi: 10.1371/journal.pone.0180015. eCollection 2017.

39.

Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.

Montgomery MP, Nakasujja N, Morawski BM, Rajasingham R, Rhein J, Nalintya E, Williams DA, Huppler Hullsiek K, Kiragga A, Rolfes MA, Donahue Carlson R, Bahr NC, Birkenkamp KE, Manabe YC, Bohjanen PR, Kaplan JE, Kambugu A, Meya DB, Boulware DR; COAT and ORCAS Trial Teams.

BMC Neurol. 2017 Jun 12;17(1):110. doi: 10.1186/s12883-017-0878-2.

40.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8.

41.

Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda.

Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schlech W, Kambugu A, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J.

AIDS. 2017 May 15;31(8):1196-1199. doi: 10.1097/QAD.0000000000001436. No abstract available.

PMID:
28441178
42.

A need to accelerate health research productivity in an African University: the case of Makerere University College of Health Sciences.

Nakanjako D, Akena D, Kaye DK, Tumwine J, Okello E, Nakimuli A, Kambugu A, McCullough H, Mayanja-Kizza H, Kamya MR, Sewankambo NK.

Health Res Policy Syst. 2017 Apr 21;15(1):33. doi: 10.1186/s12961-017-0196-6. Review.

43.

The Causal Effect of Tracing by Peer Health Workers on Return to Clinic Among Patients Who Were Lost to Follow-up From Antiretroviral Therapy in Eastern Africa: A "Natural Experiment" Arising From Surveillance of Lost Patients.

Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, Braitstein P, Somi G, Kambugu A, Bukusi E, Hartogensis W, Glidden DV, Wools-Kaloustian K, Yiannoutsos C, Martin J, Geng EH; East Africa International Epidemiologic Databases to Evaluate AIDS (EA-IeDEA) Consortium.

Clin Infect Dis. 2017 Jun 1;64(11):1547-1554. doi: 10.1093/cid/cix191. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433.

44.

Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.

Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR.

J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.

45.

Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.

von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B.

AIDS Res Ther. 2017 Jan 5;14(1):1. doi: 10.1186/s12981-016-0128-5.

46.

Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.

Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D'Alessandro U, Kambugu A, Baraka V, Rosanas-Urgell A, Lutumba P, Van Geertruyden JP.

Lancet Glob Health. 2017 Jan;5(1):e60-e68. doi: 10.1016/S2214-109X(16)30236-4. Epub 2016 Nov 11.

47.

The frequency distribution of vitamin D Receptor fok I gene polymorphism among Ugandan pulmonary TB patients.

Acen EL, Worodria W, Mulamba P, Kambugu A, Erume J.

F1000Res. 2016 Jul 29;5. pii: ISCB Comm J-1890. eCollection 2016.

48.

Initiation of antiretroviral therapy based on the 2015 WHO guidelines.

Kuznik A, Iliyasu G, Habib AG, Musa BM, Kambugu A, Lamorde M.

AIDS. 2016 Nov 28;30(18):2865-2873.

PMID:
27662547
49.

Facility-Level Factors Influencing Retention of Patients in HIV Care in East Africa.

Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen CR, Bukusi EA, Kambugu A, Bwana MB, Somi GR, Geng EH, Musick B, Yiannoutsos CT, Wools-Kaloustian K, Braitstein P.

PLoS One. 2016 Aug 10;11(8):e0159994. doi: 10.1371/journal.pone.0159994. eCollection 2016.

50.

Innovative Demand Creation for Voluntary Medical Male Circumcision Targeting a High Impact Male Population: A Pilot Study Engaging Pregnant Women at Antenatal Clinics in Kampala, Uganda.

Semeere AS, Castelnuovo B, Bbaale DS, Kiragga AN, Kigozi J, Muganzi AM, Coutinho AG, Kambugu A.

J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 4:S273-9. doi: 10.1097/QAI.0000000000001041.

Supplemental Content

Loading ...
Support Center